Semi -automated standardisation of melanin bleaching procedures of heavily pigmented melanocytic lesions for immunohistochemical analysis on an automated platform.

Semi -automated standardisation of melanin bleaching procedures of heavily pigmented melanocytic lesions for immunohistochemical analysis on an automated platform. Br J Biomed Sci. 2019 May 30; Authors: Orchard GE, Gabriel J, Shams M, Fernando P, Satoc J, Nwokie T, Ismail F, d'Amico C Abstract The diagnosis of heavily pigmented melanocytic lesions is problematic. This is often compounded by lack of visibility of nuclear detail of tumour cells due to physical masking by melanin pigment. Similarly there can be colour merging of chromogenic final reaction products with melanin, making evidence of antigenic localisation problematic. There are a number of melanin bleaching techniques available, the most widely employed method for immunohistochemical assessments is the use of dilute hydrogen peroxidase. All methods to date have involved the bleaching of melanin as a manually performed primary step before loading subsequently bleached slides onto automated immunohistochemical platforms. Here we define a semi- automated bleaching procedure that allows full integration on one of the most widely employed automated IHC staining platforms (Roche Ventana BenchMark Ultra). The bleaching protocol was defined on the BenchMark Ultra and involved the assessment of 24 histological cases of heavily pigmented malignant melanoma lesions (13 cutaneous and 11 metastatic) routinely fixed processed and paraffin wax embedded. Completion of the bleaching was assessed on H&E preparat...
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Related Links:

CONCLUSION: Accurate assessment of the regional lymph node status by SNB is becoming even more important in the era of novel effective adjuvant therapies for microscopic nodal disease. Whether complete lymph node dissection is performed in patients with a positive SN needs to be assessed individually. In the case of "active nodal surveillance" instead of surgery, long-term close follow-up in specialized centers, including ultrasonographic controls, is required. PMID: 31605168 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
CONCLUSIONS: STAT3-induced upregulation of SNHG17 contributed to the progression of melanoma by promoting the PI3K-AKT signaling. PMID: 31599425 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Ståhle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C, Srivastava B, Krueger G Abstract To the Editor: Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especially elevated among those who previously received systemic treatment or phototherapy.2 Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase suscept...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Getting a reliable diagnosis of melanoma can be a significant challenge for pathologists. The diagnosis relies on a pathologist ’s visual assessment of biopsy material on microscopic slides, which can often be subjective. Now, UCLA researchers have found that obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology can help improve the accuracy and reliability of diagnosing melanoma, one of the deadliest and most aggressive forms of skin cancer.“A diagnosis is the building block on which all other medical treatment is based,” said Dr. Joann ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Pancreatic cancer is a rare cancer that carries a poor 5 year survival rate of approximately 5% [1]. Approximately 5% to 10% of individuals with pancreatic cancer report having a closely related family member also being diagnosed with pancreatic cancer [2]. Several known genetic syndromes, such as hereditary breast-ovarian cancer syndrome (HBOC) [3], Lynch syndrome [4], familial adenomatous polyposis [5], familial atypical multiple mole melanoma syndrome [6], hereditary pancreatitis [7], Peutz-Jeghers syndrome [8], and Li-Fraumeni syndrome [9] are associated with increased risk of pancreatic cancer.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Abstract In non-pigmented skin tumors the diagnosis is mainly based on the evaluation of the vascular morphology and vessels´ distribution dermoscopically [1-4]. However, up to date, no study formally correlated the prevailing vascular morphology with the thickness of melanoma according to Breslow and amount of pigmentation. PMID: 31605621 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Oncology, News, Source Type: news
Conditions:   Melanoma;   Non-melanoma Skin Cancer Intervention:   Device: Deep Ensemble for the Recognition of Malignancy (DERM) Sponsors:   Skin Analytics Limited;   Innovate UK Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Malignant Melanoma Interventions:   Genetic: delolimogene mupadenorepvec;   Biological: atezolizumab Sponsors:   Lokon Pharma AB;   Precision Oncology LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Melanoma;   Non-melanoma Skin Cancer Intervention:   Device: Deep Ensemble for the Recognition of Malignancy (DERM) Sponsors:   Skin Analytics Limited;   Innovate UK Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biomedical Science | Cancer & Oncology | Laboratory Medicine | Melanoma | Science | Skin Cancer | UK Health